Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by megaflopon Feb 09, 2023 7:57pm
183 Views
Post# 35278537

RE:CAR-T Presentation at Summit

RE:CAR-T Presentation at SummitFrom Houra Loghmani: "I am excited to announce that I will be presenting at the upcoming CAR TCR Europe conference in London, on the potential therapeutic benefits of combining CAR T cell therapy with the oncolytic virus, pelareorep. This research is a result of a collaborative effort between Oncolytics Biotech and the amazing team of Prof. Vile from Mayo Clinic. In addition, I am also honored to be a panelist in the critical session on exploring "diversity in clinical trials". It is imperative that we address the significance of ensuring that clinical trials accurately reflect the diversity of the populations they serve and that everyone has access to effective treatments, regardless of their background. This session will be held on the 21st of Feb at 4 pm, see you there :)"
<< Previous
Bullboard Posts
Next >>